More than 60% of participant dietary consumption plans showed no significant difference between omalizumab and multi-food oral immunotherapy success rates…
Addition of highly regarded and accomplished partners, Emily Johnson and Mark Stagliano, further enhances the firm’s premier, fully integrated corporate…